Articles by Blood Cancers Today Staff Writers
The phase III study included patients who received at least one prior line of therapy.
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Brexucabtagene autoleucel is a promising therapy in relapsed or refractory MCL.
A research team sought in their study to determine if the IPSS-M could also apply to CMML.
Pirtobrutinib can be safely used along with concomitant antithrombotic therapy (CAT) in treating B-cell malignancies.
The overall response rate was 83.8% and the CR rate was 73% after the median follow-up of eight months.
A first-line induction regimen that alternates VR-CAP with R-DHAP can improve treatment response in newly diagnosed MCL.
Allogeneic HSCT can yield favorable outcomes in treating patients with therapy-related MDS.
A presentation by Dr. Rami Komrokji at the Eleventh SOHO Annual Meeting gave additional insights into the COMMANDS trial.
Luspatercept is highly effective in treating ESA-naïve patients with LR-MDS.
Response rates were high, and OS was improved in patients receiving venetoclax, although not statistically significant.
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
Researchers are evaluating the combination to establish a recommended phase III dose for the first-line setting.
In the trial, patients received talquetamab at 0.4 mg/kg weekly or 0.8 mg/kg every two weeks.
CAR T-cell therapy with lisocabtagene maraleucel resulted in survival benefits for patients with relapsed or refractory.
Older adult patients with newly diagnosed Ph- ALL may benefit from this combination therapy.
Patients treated with the higher dose had higher overall response rates.
Approximately one-third of the heavily pretreated patients in the small study responded to therapy.
The overall response rate was 87.8% with 73% of patients achieving complete response.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.